Vicarius Pharma, a Kuessnacht, Switzerland—based provider of a novel approach for U.S.-based bio-pharmaceutical companies to commercialize their first asset in European markets, secured a CHF21m (approx. $21.8m) in Series A financing.
James Mullen, CEO of Patheon, former CEO of Biogen, and executive chairman of Vicarius’ board, was the lead investor in a round that includes private backers.
Led by CEO Hans Peter Hasler (former COO of Elan and Biogen), and a team of experts in regulatory and pricing strategies, stakeholder/KOL management,
Vicarius Pharma provides U.S.-based bio-pharmaceutical companies with a new process to commercialize their first product across Europe retaining control of their assets without having to out-license to a larger pharmaceutical partner or build their own commercial organization overseas.
The company acts as the go-to-market organization for Europe, building a customer-facing organization and commercializing the asset in the client’s name, while absorbing all launch costs.
In a partnership with Vicarius, companies retain strategic control over R&D, plus the flexibility to recover at any time the asset and dedicated organization built by Vicarius.